<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04068896</url>
  </required_header>
  <id_info>
    <org_study_id>18-0402</org_study_id>
    <nct_id>NCT04068896</nct_id>
  </id_info>
  <brief_title>Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy</brief_title>
  <official_title>A Phase 1/2 Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NGM Biopharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NGM Biopharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2019</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>19 weeks</time_frame>
    <description>The number and percent of patients reporting treatment emergent adverse events (TEAEs) by cohort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of NGM120</measure>
    <time_frame>19 weeks</time_frame>
    <description>NGM120 concentration data by cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Anticancer Activity</measure>
    <time_frame>19 weeks</time_frame>
    <description>Assessed using the RECIST Version 1.1 criteria</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Metastatic Castration-resistant Prostate Cancer</condition>
  <condition>Bladder Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Head Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>NGM120 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM120 Subcutaneous Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGM120 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM120 Subcutaneous Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGM120 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM120 Subcutaneous Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGM120 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM120 Subcutaneous Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGM120 Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM120 Subcutaneous Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGM120 Dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM120 Subcutaneous Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM120</intervention_name>
    <description>NGM120 Dose 1</description>
    <arm_group_label>NGM120 Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM120</intervention_name>
    <description>NGM120 Dose 2</description>
    <arm_group_label>NGM120 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM120</intervention_name>
    <description>NGM120 Dose 3</description>
    <arm_group_label>NGM120 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM120</intervention_name>
    <description>NGM120 Dose 4</description>
    <arm_group_label>NGM120 Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM120</intervention_name>
    <description>NGM120 Dose 5</description>
    <arm_group_label>NGM120 Dose 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM120</intervention_name>
    <description>NGM120 Dose 6</description>
    <arm_group_label>NGM120 Dose 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have histologically confirmed advanced or metastatic castration-resistant prostate&#xD;
             cancer, bladder cancer, melanoma, non-small cell lung cancer, pancreatic cancer,&#xD;
             colorectal cancer, gastric cancer, esophageal cancer, ovarian cancer, and head neck&#xD;
             squamous cell carcinoma.&#xD;
&#xD;
             Or,&#xD;
&#xD;
             Have histologically confirmed metastatic pancreatic adenocarcinoma. Recurrent&#xD;
             unresectable pancreatic cancer is acceptable as long as the treatment is first-line.&#xD;
&#xD;
          2. Have not received any approved chemotherapy, except in the adjuvant setting.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject was using immunosuppressive medications within 14 days before Screening with&#xD;
             the exception of topical (intranasal, inhaled, and local injection), systemic&#xD;
             (prednisone equivalent 10 mg/day or less), or as needed for hypersensitivity reactions&#xD;
             such as computed tomography (CT) scan premedication.&#xD;
&#xD;
          2. Subject has active infections or other serious underlying significant medical illness,&#xD;
             abnormal and clinically significant laboratory findings or psychiatric illness/social&#xD;
             situation.&#xD;
&#xD;
          3. Subject is using a pacemaker, implantable cardiac defibrillator, neurostimulator,&#xD;
             cochlear implants, cochlear implants, or other electronic medical equipment.&#xD;
&#xD;
          4. Subject has documented immunodeficiency or organ transplant.&#xD;
&#xD;
          5. Subject has an untreated central nervous system disease, leptomeningeal disease or&#xD;
             cord compression.&#xD;
&#xD;
          6. Subject has a history, or presence, of significant cardiovascular diseases; including&#xD;
             uncontrolled hypertension, clinically relevant cardiac arrhythmia, unstable angina or&#xD;
             myocardial infarction within 6 months before randomization, congestive heart failure &gt;&#xD;
             New York Heart Association Class II, severe peripheral vascular disease, corrected QT&#xD;
             (QTc) prolongation &gt;470 msec, clinically significant pericardial effusion.&#xD;
&#xD;
          7. Subject has a history or presence of documented inflammatory bowel disease.&#xD;
&#xD;
          8. Subject is known to be positive for human immunodeficiency virus infection.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NGM Study Director</last_name>
    <role>Study Director</role>
    <affiliation>NGM Biopharmaceuticals, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>NGM Study Director</last_name>
    <phone>650-243-5555</phone>
    <email>ngm120@ngmbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 122</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90084</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 105</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>98517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 108</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 113</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 102</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 110</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 117</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 120</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 119</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Lewiston</city>
        <state>Maine</state>
        <zip>04240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 106</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 103</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 115</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 111</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 123</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 104</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 125</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 124</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 101</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 116</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 118</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 127</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 107</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 126</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 109</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 112</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 22, 2019</study_first_submitted>
  <study_first_submitted_qc>August 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

